Integral Diagnostics Limited (ITGDF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Integral Diagnostics Limited $0.79, price $2.61, upside -69.8%, quality 26 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Integral Diagnostics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
44‑month range $0.8098 – $2.61 · fair‑value band $0.2200 – $0.7900 · the $2.61 price screens above the $0.7900 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Integral Diagnostics in your weekly email
Every Wednesday you see whether Integral Diagnostics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand.
Show more
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as x-ray and EOS. Integral Diagnostics Limited was founded in 1967 and is headquartered in Melbourne, Australia.
Stock analysis
Integral Diagnostics Limited (ITGDF) currently trades at $2.61, while our model-based Fair Value estimate is $0.7900, 69.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of $0.8700 per share, and 0 of the 19 models we run sit above the $2.61 price.
Bear case: the Earnings-Based group reads lowest at $0.1800, and 19 of the 19 models stay below the price. Evidence for this calculation is high.
Scenario range: $0.2200 (bear) to $0.7900 (bull), the price of $2.61 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Integral Diagnostics Limited reported revenue of A$627M in FY2025 versus A$349M in FY2021, a compound +15.8%/yr. Reported net income was A$4.7M in FY2025, compounding −37.8%/yr from FY2021.
Key figures
Market cap $373M · P/E ratio 100.0 · P/S ratio 0.75 · EPS (TTM) $0.0100 · Dividend yield 2.8% · Net margin 0.7% · Return on equity 2.1% · Return on assets (EBIT) 5.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 223% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −70%, ITGDF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($0.1500 to $1.31). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $0.2200Fair Value $0.7900Bull $0.7900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.73/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+33.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.1%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−5.5%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.3%
Dividend (yield on the price)2.8%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.17% → 9%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+45.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+14.4%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in AUD, Australia: IMF forecast 3.0% a year to 2030, 2.9% from 2016 to 2025) that is about +41.2% a year for the price and +11.1% for the forecasts.
Compare Integral Diagnostics Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 134 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score26 · Bottom 25%
Fair Value upside+7.9% · Above median
Profitability
Return on equity (TTM)2.1% · Below median
Return on assets3.2% · Above median
Net margin (TTM)1.8% · Below median
Operating margin (TTM)8.5% · Below median
Growth and dividend
Revenue growth55.6% · Top 25%
Dividend yield (TTM)2.8% · Above median
Balance sheet
Debt / equity0.49× · Highest 25%
Valuation Multiplesvs Diagnostics & Research median · lower = cheaper
P/E (TTM)100.0× · Priciest 25%
P/B0.78× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Integral Diagnostics Limited (ITGDF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.7900 versus the last price from Sep 25, 2026 of $2.61, about −70% upside (overvalued).
What is the fair value of ITGDF?
Our model-based fair value for Integral Diagnostics Limited is $0.7900 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $2.61.
What is the quality score of ITGDF?
Integral Diagnostics Limited has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Integral Diagnostics Limited (ITGDF)?
Our model-based price target is the fair value of $0.7900 (as of Sep 24, 2026) from 20 valuation models. Cautious scenario $0.2200, optimistic scenario $0.7900. It is a calculation from audited fundamentals, not an analyst target.
What is the Integral Diagnostics Limited stock forecast for 2026?
Our models put fair value at $0.7900, about −70% upside versus the last price from Sep 25, 2026 of $2.61 (overvalued). Cautious scenario $0.2200, optimistic scenario $0.7900. The calculation is refreshed regularly with new filings.
What is the revenue of Integral Diagnostics Limited (ITGDF)?
Integral Diagnostics Limited reported trailing-twelve-month revenue of about A$768M (latest available figure, as of Sep 24, 2026).
Does Integral Diagnostics Limited pay a dividend?
Integral Diagnostics Limited currently shows a dividend yield of about 2.79% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Integral Diagnostics Limited (ITGDF)?
For today's price to be fair in a discounted-cash-flow model, Integral Diagnostics Limited would have to grow free cash flow by +45.4 % per year for five years (discount rate 9.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +18.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of ITGDF use?
Our models discount Integral Diagnostics Limited at 9.8 %: a base by market capitalisation (small), damped by beta 0.11, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Integral Diagnostics Limited that is +45.4 % per year a year over ten years, using the same discount rate (9.8 %) and the same formula as our fair value.
How much growth has Integral Diagnostics Limited (ITGDF) delivered so far?
Over the past 5 years revenue at Integral Diagnostics Limited grew +18.0 % a year. The price currently implies +45.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Integral Diagnostics Limited (ITGDF) growing?
The median revenue growth in the sector is +5.1 % a year. That is the yardstick for the growth priced into Integral Diagnostics Limited (+45.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Integral Diagnostics Limited (ITGDF)?
The free-cash-flow yield on the price is 1.00 %: that much free cash flow Integral Diagnostics Limited produces per unit of market value. When it exceeds the discount rate of our models (9.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Integral Diagnostics Limited (ITGDF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Integral Diagnostics Limited it is $0.7900 per share (as of Sep 24, 2026), against a price of $2.61. It is the blended result of 20 valuation models (cash flow, earnings, asset, dividend).
Is Integral Diagnostics Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ITGDF trades above its calculated fair value: price $2.61, fair value $0.7900, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ITGDF?
No. The price is what the market pays today ($2.61); the fair value is what the company's own numbers justify ($0.7900). For Integral Diagnostics Limited the two are $1.82 per share apart. That gap is exactly why we show both numbers side by side.
How much is Integral Diagnostics Limited worth?
The market values Integral Diagnostics Limited at about $373M (market capitalisation, as of Sep 24, 2026). Per share that is $2.61; our models calculate a fair value of $0.7900 per share.
What do the bullish and bearish scenarios say about ITGDF?
Our models span a range for Integral Diagnostics Limited: cautious scenario $0.2200, base $0.7900, optimistic $0.7900 per share (as of Sep 24, 2026, price $2.61). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ITGDF?
Integral Diagnostics Limited trades at a price-to-earnings ratio of 100.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.7900 is built from several models across several years. Other multiples: P/B 0.8, P/S 0.7, EV/EBITDA 7.8.
How solid is the balance sheet of Integral Diagnostics Limited (ITGDF)?
Balance-sheet figures for Integral Diagnostics Limited (as of Sep 24, 2026): return on equity 2.1%, debt of 0.49 per unit of equity. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is ITGDF from its 52-week high?
Integral Diagnostics Limited trades at $2.61, at its 52-week high of $2.61 and 223% above the low of $0.8098 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.7900 is for.
Which stocks are comparable to Integral Diagnostics Limited?
From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, WuXi AppTec Co, Agilent Technologies, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Integral Diagnostics Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $2.61, calculated fair value $0.7900 (−70%), Quality Score 26/100, from 20 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ITGDF calculated?
We run Integral Diagnostics Limited through 20 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.7900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Integral Diagnostics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Integral Diagnostics Limited (ITGDF)?
The latest price we hold is from Sep 25, 2026 and stands at $2.61. Our model-based fair value is $0.7900, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Integral Diagnostics Limited right now?
The price sits above even our optimistic bull case ($0.7900). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($0.2200 to $0.7900). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of Integral Diagnostics Limited
How large is the market capitalisation of Integral Diagnostics Limited (ITGDF)?
The market capitalisation of Integral Diagnostics Limited is $373M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Integral Diagnostics Limited (ITGDF)?
The price-to-sales ratio of Integral Diagnostics Limited is 0.75 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Integral Diagnostics Limited (ITGDF)?
Earnings per share at Integral Diagnostics Limited are $0.0100 (price ÷ EPS = P/E 100.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Integral Diagnostics Limited (ITGDF)?
The dividend yield of Integral Diagnostics Limited is 2.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Integral Diagnostics Limited (ITGDF)?
The net margin of Integral Diagnostics Limited is 0.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Integral Diagnostics Limited (ITGDF)?
The return on equity (ROE) of Integral Diagnostics Limited is 2.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Integral Diagnostics Limited (ITGDF)?
On an EBIT basis the return on assets of Integral Diagnostics Limited is 5.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Integral Diagnostics Limited (ITGDF)?
The operating margin of Integral Diagnostics Limited is 8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Integral Diagnostics Limited (ITGDF)?
Revenue at Integral Diagnostics Limited is growing +55.6% versus a year earlier (3y avg +20.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Integral Diagnostics Limited (ITGDF)?
Earnings per share at Integral Diagnostics Limited are growing −47.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Integral Diagnostics Limited (ITGDF) carry?
The net debt of Integral Diagnostics Limited is A$289M (fiscal year 2025, ≈ 20.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Integral Diagnostics Limited in the live analysis
One click puts Integral Diagnostics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026